Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verteporfin PDT for Chronic CSC
NCT00211445Phase 2Completed
- Sponsor
- Manhattan Eye, Ear and Throat Hospital
- Start
- Jul 2002
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of verteporfin in Central Serous Chorioretinopathy (CSCR), sponsored by Manhattan Eye, Ear and Throat Hospital. Primary endpoints: Mean change in Visual Acuity (ETDRS) at 24 months and Investigate the potential of photodynamic therapy using verteporfin at 24 months. Started Jul 2002; status: completed.
02
Drugs
verteporfin
03
Conditions
Central Serous Chorioretinopathy (CSCR)
Beyond the preview
Go deeper on NCT00211445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00211445.